K
Kodiak Sciences D
D
KOD
37.040
USD
0.90
(2.50%)
قبل الجلسة·36.150USD-0.890(-2.40%)
حجم التداول
21,790
الربح لكل سهم
-3
العائد الربحي
-
P/E
-9
حجم السوق
2,311,647,611
العنوان: Kodiak Sciences
القطاع: Healthcare
الصناعة: Biotechnology
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.